Search

The aim of this study was to report the clinical and radiographic outcomes of 21 patients with severe thoracic kyphosis who underwent surgical correction by pedicle subtraction osteotomy. A retrospective multicentric study was conducted among a sample of patients who underwent single-stage correction via a posterior surgical approach. Pedicle subtraction osteotomy (PSO) was performed in all patients who presented a kyphotic deformity exceeding 70°. The cohort included 5 males and 16 females, with an average age of 62.7 years at the time of surgery. The minimum follow-up was 36 months, and the mean follow-up was 39.3 months. Following surgery, kyphosis across the treated segments was reduced by an average of 26.5°. Both back pain and neurological function improved after surgical treatment. There was a 68.2% improvement in VAS scores. Severe thoracic kyphosis can be improved through corrective surgery, and deformity correction can be accompanied by improvement in clinical symptoms. [ABSTRACT FROM AUTHOR]

Osteogenesis imperfecta (OI) is an hereditary disease characterized by low bone mass, increased bone fragility, short stature, and skeletal deformities, few treatment options are currently available. Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of OI and Paget's disease of bone. A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing an useful system for administration in homecare. Neridronate appears to increase Bone Mineral Density (BMD) in adults with OI and reduces bone resorption by inhibition of osteoclastic activity. Teriparatide (recombinant 1-34 N terminal sequence of human parathyroid hormone) is the first anabolic agent approved for the treatment of patients with osteoporosis and has been reported to increase bone formation by stimulating osteoblast differentiation, osteoblast function, and survival. The results of this study showed a promising role of teriparatide in the therapy of OI type I. [ABSTRACT FROM AUTHOR]

Competing Interests: All the authors have no conflict of interest to declare.

Osteogenesis imperfecta (OI) is an hereditary disease characterized by low bone mass, increased bone fragility, short stature, and skeletal deformities, few treatment options are currently available. Neridronate is an amino-bisphosphonate, licensed in Italy for the treatment of OI and Paget's disease of bone. A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing an useful system for administration in homecare. Neridronate appears to increase Bone Mineral Density (BMD) in adults with OI and reduces bone resorption by inhibition of osteoclastic activity. Teriparatide (recombinant 1-34 N terminal sequence of human parathyroid hormone) is the first anabolic agent approved for the treatment of patients with osteoporosis and has been reported to increase bone formation by stimulating osteoblast differentiation, osteoblast function, and survival. The results of this study showed a promising role of teriparatide in the therapy of OI type I.